Report of Foreign Issuer (6-k)
July 25 2017 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of July 2017
Commission File No.: 001-35773
REDHILL BIOPHARMA LTD.
(Translation of registrant's name into English)
21 Ha'arba'a Street, Tel Aviv, 64739, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Attached hereto and incorporated by reference herein is a press release issued by the Registrant entitled: "
RedHill Biopharma Reports 2017 Second Quarter Financial Results
”
Exhibit 1: Registrant's press release entitled "
RedHill Biopharma Reports 2017 Second Quarter Financial Results
”.
Exhibit 2: Registrant’s condensed consolidated interim unaudited financial information as of June 30, 2017 and for the three months then ended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
REDHILL BIOPHARMA LTD.
|
|
|
(Registrant)
|
|
|
|
|
|
|
Date: July 25, 2017
|
|
By:
/s/ Dror Ben-Asher
|
|
|
Dror Ben-Asher
|
|
|
Chief Executive Officer
|
|
|
|
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Apr 2023 to Apr 2024